Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Interactions between the innate immune and blood coagulation systems

Charles T. Esmon

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; Depts of Pathology, and Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center; and Howard Hughes Medical Institute, Oklahoma City, OK 73104, USA

Blood coagulation and inflammation are universal responses to infection and there is crosstalk between inflammation and coagulation that can either amplify or dampen the responses. Loss of appropriate interactions between these systems probably contributes to morbidity and mortality in infectious diseases. For instance, inflammatory cytokines and leukocyte elastase can downregulate natural anticoagulant proteins that help to maintain endothelial-cell integrity, control clotting, inhibit vasoactive peptides and dampen leukocyte infiltration into the vessel wall. This Review will summarize our current understanding of the mechanisms involved in the crosstalk between these two important systems.

When infectious agents, regardless of their nature, initiate the innate immune response, it in turn triggers blood coagulation [1]. For instance, as viral infections, such as severe acute respiratory syndrome (SARS), progress into severe sepsis, markers of blood coagulation are increased markedly [2]. Blood coagulation components are not simply bystanders but can either amplify or inhibit the inflammatory response. Blood clotting can be initiated when tissue factor to the blood then triggers the coagulation cascade. Complement activation can lead to the formation of plasma membrane surfaces enriched in negatively charged phospholipids that amplify the coagulation reactions [4,5].

Opposing this coagulation cascade are the natural anticoagulant pathways. These pathways not only limit the coagulation response but also dampen the inflammatory response by minimizing leukocyte chemotaxis [6] and endothelial-cell interactions [7], and by suppressing apoptosis [8,9] and reducing cytokine expression [10–12]. However, the acute inflammatory response can lead to suppression of the natural anticoagulant pathways by consumption, proteolytic inactivation and downregulation of protein expression [13]. Loss of the coordinate control of the coagulation and inflammation pathways due to impaired function of the natural anticoagulant systems probably contributes to organ failure in severe sepsis.

The blood clotting process is extremely complex (the more biochemical details are reviewed in Refs [14,15]). Briefly, blood coagulation is initiated when tissue factor comes into contact with blood (Figure 1). Under normal circumstances, there is little tissue factor in the intravascular compartment. Most of the tissue factor is found constitutively expressed on extravascular cells, where it surrounds the vessels providing a mechanism to rapid seal breaches in vessel integrity [16]. Recent studies have indicated that there is a circulating form of tissue factor, probably localized on leukocyte-derived microparticles [17–19]. This microparticle-bound tissue factor might be concentrated on P-selectin on activated platelets in forming thrombi through interaction with its ligand, PSGL 1 (P-selectin glycoprotein ligand 1), from the activated leukocytes. Inflammatory stimuli can increase this response, both by stimulating tissue factor synthesis and promoting microparticle formation. Microparticles express high levels of negatively charged phospholipids on their surface [5], thus promoting both the tissue factor–factor VIIa-mediated factor X and IX activation, and enabling the propagation of coagulation by the factor Xa–factor Va activation of prothrombin and the factor IXa–factor VIIIa activation of factor X. Potent platelet agonists, such as thrombin in combination with collagen or complement C5b-9, can further augment the availability of negatively charged phospholipid membrane surfaces on cells, particularly platelets, thus enabling further amplification of the coagulation system [5,20]. Once initiated, the coagulation pathway has the potential to generate ~100 times more thrombin than is required to form a rapid, firm clot. Under most conditions, this is prevented by the natural anticoagulant mechanism. The major inhibitory mechanisms involve the protein C anticoagulant pathway, antithrombin–heparin, and the tissue factor pathway inhibitor (TFPI).

The protein C pathway is triggered when thrombin binds to thrombomodulin on the endothelial-cell surface. This complex, in concert with protein C bound to the endothelial-cell protein C receptor (EPCR), generates activated protein C. Once activated, protein C dissociates from the EPCR and can bind to protein S on membrane...
surfaces. The activated protein C–protein S complex then inactivates factors Va and VIIIa. Without these cofactors, factor Xa and factor IXa have much less than 1% of the capacity to activate the downstream zymogen. Practically, this means that inactivation of the cofactors shuts off the coagulation system completely. In addition, relative to thrombin in solution, thrombin bound to thrombomodulin is inhibited much more rapidly by antithrombin and protein C inhibitor [21].

The antithrombin–heparin mechanism neutralizes factor Xa, thrombin and factor IXa. It also inactivates factor VIIa but only when the factor VIIa is bound to tissue factor [22,23]. Antithrombin inhibition of the factor VIIa–tissue factor complex, factor IXa, factor Xa and thrombin are all thought to be accelerated by vascular heparin-like proteoglycans [24].

TFPI inactivates factor VIIa bound to tissue factor using a unique mechanism. The inhibitor has two functional inhibitory Kunitz domains. The second domain binds to and inhibits factor Xa, which, as a result of its ability to bind negatively charged membranes, concentrates the TFPI–factor Xa complex on the membrane surface, at which time the first Kunitz domain of the inhibitor reversibly neutralizes factor VIIa.

The physiological significance of these pathways is demonstrated by gene experiments in mice, which result in embryonic or neonatal lethality when any single pathway is disrupted [25–29]. In humans, complete deficiencies of protein C lead to neonatal microvascular thrombosis (purpura fulminans) and subsequent death unless treated [30]. Complete deficiencies of antithrombin and the TFPI in humans have not been described.

Impact of acute inflammatory responses on natural anticoagulant mechanisms

Inflammation has multiple effects on the coagulation system (Figure 2). Antithrombin is consumed and/or inactivated in sepsis and other acute inflammatory injury. Antithrombin inhibitory activity decreases markedly during severe sepsis, often to <50% of normal levels [31]. Because the rates of inhibition of the target proteases are strongly dependent on the antithrombin concentration, this decrease in inhibitor concentration would contribute to increased stability of the coagulation enzymes and hence favor intravascular coagulation.

There is evidence that the vascular heparin-like molecules are reduced by inflammatory cytokines and neutrophil activation products [32]. Clinically, in severe sepsis, these heparin-like molecules can be downregulated or degraded [33], further diminishing the natural anticoagulant potential, especially when the antithrombin level has been reduced by consumption.

The protein C pathway appears to be especially sensitive to downregulation by inflammatory responses. Interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and endotoxin can downregulate thrombomodulin and the EPCR by inhibiting gene transcription [34,35], reducing the ability to generate activated protein C. Neutrophil
elastase cleaves thrombomodulin from the endothelial-cell surface, generating a much less active form of thrombomodulin [36]. In septic patients, both the EPCR and thrombomodulin can be severely downregulated, as demonstrated both immunohistochemically [37] and by analysis of the ability of the patients to generate activated protein C [38]. In addition, protein C levels decrease dramatically in patients with severe sepsis. This is probably due to a combination of consumption and liver (the main site of protein C synthesis) dysfunction. The degree of protein C reduction correlates with a negative prognosis in septic patients [39].

Once tight control of thrombin and other coagulation enzymes is lost, they can participate in promoting the inflammatory response (Figure 3). The enhanced inflammatory response enhances the cell-associated coagulation activities as described earlier. Therefore, anticoagulants that dampen the cellular inflammatory response also dampen the coagulant response [40].

**Impact of natural anticoagulant mechanisms on the inflammatory response and cellular apoptosis**

The antithrombin–heparin pathway can modulate inflammatory responses not only by inhibiting coagulant enzyme-mediated cell signaling through the protease activated receptors but also by modulating cellular responses [12]. Antithrombin can downregulate the expression of CD11b/CD18 on leukocytes. Because factor X binding to this receptor augments factor X activation [41,42], the downregulation of this cellular factor X receptor decreases both leukocyte adhesion and coagulation. The addition of antithrombin to endothelial cells in culture increases prostacyclin formation [43] and decreases NF-κB signaling [10]. By modulating cellular responses to endotoxin, antithrombin appears to decrease both tissue factor and IL-6 expression in monocytes and endothelium [40]. Antithrombin binding to syndecan 4, a proteoglycan on neutrophils, inhibits chemokine-induced neutrophil migration [44]. Interestingly, heparin blocks this effect. In addition, administration of high levels of antithrombin to septic experimental animals and animals undergoing ischemia reperfusion injury reverses leukocyte recruitment [45] (Figure 4).

The protein C anticoagulant pathway has several components that reduce the inflammatory response. Thrombomodulin not only increases protein C activation but also prevents thrombin from activating protease-activated receptors (PARs) [46,47]. This is accomplished at least in part because the site on thrombin (anion binding exosite 1) responsible for binding PAR1 and thrombomodulin overlap (Figure 5). In addition, thrombin bound to thrombomodulin gains the ability to activate a plasma procarboxypeptidase R [also known as thrombin activatable fibrinolysis inhibitor (TAFI)] [48]. Recent studies have shown that his carboxypeptidase is a very potent inhibitor of the complement anaphylatoxin, C5a [49,50], and bradykinin [50]. By inhibiting these vasoactive

![Figure 2. The impact of inflammatory mediators on the regulation of coagulation. Inflammatory mediators, such as TNF-α or endotoxin, can effect the changes indicated. An upward arrow indicates increases in levels and a downward arrow indicates decreases. Abbreviations: α1-AT, α1 antitrypsin; EPCR, endothelial-cell protein C receptor; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α.](image_url)

![Figure 3. Thrombin is a multifunctional enzyme. Thrombin generates procoagulant, anticoagulant, inflammatory and mitogenic responses. These responses shift the hemostatic balance. Abbreviations: CD40L, CD40 ligand; EC, endothelial cell; IL-6, interleukin-6; MCP-1, macrophage chemotactic protein-1; PAF, platelet activating factor; PDGF, platelet-derived growth factor; PMNs, polymorphonucleocytes; TGF-β, transforming growth factor-β. Reproduced with permission from Ref. [77].](image_url)
Activated protein C dampens NF-κB signaling in monocytes [53–55]. It also decreases inflammatory mediator-initiated generation of tissue factor on leukocytic cell lines [12,56,57] in an EPCR dependent fashion. In addition, activated protein C can inhibit tight neutrophil adhesion to the endothelium [6]. Activated protein C can also decrease endothelial-cell apoptosis [9]. This function is dependent on the EPCR and apparently involves activation of PAR1 [58]. In mouse models of stroke, activated protein C minimizes damage at least in part by inhibiting apoptosis through downregulation of P53 [59]. This inhibition of P53 expression was also dependent on EPCR and PAR1. How activating PAR1 generates anti-inflammatory activities remains an area of active investigation.

The recent determination of the EPCR structure suggests additional potential roles of the protein C pathway in regulating the immune response. EPCR shares considerable sequence identity to the MHC I–CD1 family of molecules [35]. The crystal structure of EPCR reveals that, like the CD1 family, EPCR has a tightly bound lipid, in this case phospholipid, located in a region virtually identical to the antigen-presenting groove in the CD1 family [60] (Figure 6). In CD1 proteins, glycolipids bind in this groove and can have a major role in the immune response to bacterial infection [61]. In addition, deficiency of CD1d in mice leads to autoimmune disease [62]. From the structural similarities, it is probable, but as yet unproven, that EPCR might have roles similar to those of CD1 molecules in the regulation of inflammation. Autoantibodies to EPCR and a correlation with autoimmune fetal loss have recently been demonstrated [63], consistent with its involvement in immune regulation.

Platelet contributions to inflammatory responses
Platelets are also involved in the linking of inflammation and coagulation. Inflammatory mediators, such as IL-6, not only increase platelet production, but the platelets that are generated are more thrombogenic, demonstrating an increased sensitivity to platelet agonists, such as thrombin [64]. Platelets contain high concentrations of the proinflammatory mediator CD40 ligand. On platelet activation, CD40 ligand is released. This protein then induces tissue factor synthesis [65,66] and increases inflammatory cytokines, such as IL-6 and IL-8 [67,68].

Conclusions
The clotting process involves molecules, such as the selectins, that were originally thought to be involved primarily in inflammation (Box 1). Natural anticoagulant proteins exhibit a spectrum of anti-inflammatory activities, including inhibiting NF-κB signaling, inhibiting complement C5a and bradykinin and preventing apoptosis. Severe acute inflammatory challenges can down-regulate the natural anticoagulants, thereby diminishing their ability to dampen the coagulant and inflammatory responses. When this happens, a progressive cycle can evolve in which the coagulation increases the inflammatory response, thereby increasing the coagulant response until severe vascular and organ injury occurs. Modulation of this complex series of interactive events promises to offer an attractive method for intervening clinically in diseases involving acute inflammatory...
challenges, such as severe sepsis. The recent successful demonstration that recombinant activated protein C can reduce the 28-day all cause mortality in patients with severe sepsis [69] provides support for this proposal.

Of interest, antithrombin [70] and TFPI both failed in large randomized clinical trials [71], despite, similar to activated protein C, having proven efficacious in non-human primate models of severe sepsis [72,73]. Several possibilities could explain the failure of the natural anticoagulants TFPI and antithrombin in the trials. First, in the clinical situation, bleeding complications limit dosage to a greater extent than in the animal studies. For instance, the anticoagulant doses in the baboon sepsis model were much higher than in the human trials [74]. Therefore, the doses of the anticoagulants might not have been adequate. In the antithrombin trial, heparin was used in many of the patients [70]. As noted earlier, heparin blocks several cellular effects of antithrombin. Although there was no overall effect on survival with antithromin, the patients with heparin alone or antithrombin alone tended to have a better survival rate than the patients who received both [70].

Alternatively, the trial result differences lie in some different functions among the natural anticoagulants TFPI and antithrombin in the trials. First, in the clinical situation, bleeding complications limit dosage to a greater extent than in the animal studies. For instance, the anticoagulant doses in the baboon sepsis model were much higher than in the human trials [74]. Therefore, the doses of the anticoagulants might not have been adequate. In the antithrombin trial, heparin was used in many of the patients [70]. As noted earlier, heparin blocks several cellular effects of antithrombin. Although there was no overall effect on survival with antithromin, the patients with heparin alone or antithrombin alone tended to have a better survival rate than the patients who received both [70].

Alternatively, the trial result differences lie in some different functions among the natural anticoagulants TFPI and antithrombin in the trials. First, in the clinical situation, bleeding complications limit dosage to a greater extent than in the animal studies. For instance, the anticoagulant doses in the baboon sepsis model were much higher than in the human trials [74]. Therefore, the doses of the anticoagulants might not have been adequate. In the antithrombin trial, heparin was used in many of the patients [70]. As noted earlier, heparin blocks several cellular effects of antithrombin. Although there was no overall effect on survival with antithromin, the patients with heparin alone or antithrombin alone tended to have a better survival rate than the patients who received both [70].

Alternatively, the trial result differences lie in some different functions among the natural anticoagulants TFPI and antithrombin in the trials. First, in the clinical situation, bleeding complications limit dosage to a greater extent than in the animal studies. For instance, the anticoagulant doses in the baboon sepsis model were much higher than in the human trials [74]. Therefore, the doses of the anticoagulants might not have been adequate. In the antithrombin trial, heparin was used in many of the patients [70]. As noted earlier, heparin blocks several cellular effects of antithrombin. Although there was no overall effect on survival with antithromin, the patients with heparin alone or antithrombin alone tended to have a better survival rate than the patients who received both [70].
time of inhibitor administration. Furthermore, in the patient populations, many co-morbidities might decrease efficacy of one of the inhibitors selectively. Co-morbidities, such as atherosclerosis, diabetes and hypertension, can exacerbate the innate inflammatory response by a variety of mechanisms, including downregulation of the natural anticoagulants [75].

References

1 Opal, S.M. et al. (2003) Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin. Infect. Dis. 37, 50–58

2 Lee, N. et al. (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–1994

3 Rauch, U. et al. (2000) Transfer of tissue factor from leucocytes to platelets is mediated by CD15 and tissue factor. Blood 96, 170–175

4 Bevers, E.M. et al. (1998) Transmembrane phospholipid distribution in blood cells: control mechanisms and pathophysiological significance. Biol. Chem. 379, 973–986

5 Sims, P.J. et al. (1989) Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott Syndrome: An isolated defect in platelet procoagulant activity. J. Biol. Chem. 264, 17049–17057

6 Sturn, D.H. et al. (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102, 1499–1505

7 Isobe, H. et al. (2001) Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104, 1171–1175

8 Cheng, T. et al. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9, 338–342

9 Joyce, D.E. et al. (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276, 11199–11203

10 Oeschläger, C. et al. (2002) Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 99, 4015–4020

11 Yasui, H. et al. (2001) Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am. J. Respir. Crit. Care Med. 163, 1660–1668

12 Okajima, K. (2001) Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. 184, 258–274

13 Opal, S.M. and Esmon, C.T. (2003) Bench-to-bedside review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit. Care 7, 23–38

14 Furie, B. and Furie, B.C. (1988) The molecular basis of blood coagulation. Cell 53, 505–519

15 Esmon, C.T. (2003) Blood coagulation. In Nathan and Oski’s Hematology of Infancy and Childhood (Nathan, D.G. et al., eds), pp. 1475–1496, W.B. Saunders Company

16 Drake, T.A. et al. (1989) Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134, 1087–1097

17 Celi, A. et al. (2003) Thrombin formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J. Thromb. Haemost. 1, 60–68

18 Giesen, P.L.A. et al. (1999) Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. U. S. A. 96, 2311–2315

19 Bouchard, B.A. and Tracy, P.B. (2003) The participation of leucocytes in coagulant reactions. J. Thromb. Haemost. 1, 464–469

20 Zwaal, R.F.A. and Schroit, A.J. (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89, 1121–1132

21 Rezaie, A.R. et al. (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J. Biol. Chem. 270, 25336–25339

22 Lawson, J.H. et al. (1993) Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J. Biol. Chem. 268, 767–770

23 Rosenberg, R.D. (1987) Regulation of the hemostatic mechanism. In The Molecular Basis of Blood Diseases (Stamatoyannopoulos, G. et al., eds), pp. 534–574, W.B. Saunders Company

24 Marcum, J.A. and Rosenberg, R.D. (1984) Anticoagulantly active heparin-like molecules from the vascular tissue. Biochemistry 23, 1739–1737

25 Ishiguro, K. et al. (2000) Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Invest. 106, 873–878

26 Gu, J-M. et al. (2002) Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J. Biol. Chem. 277, 43335–43343

27 Huang, Z-F. et al. (1997) Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90, 944–951

28 Weiler-Guettler, H. et al. (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101, 1983–1991
29 Jalbert, L.R. et al. (1998) Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J. Clin. Invest. 102, 1481–1488
30 Dreyfus, M. et al. (1991) Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N. Engl. J. Med. 325, 1565–1568
31 Levi, M. and ten Cate, H. (1999) Disseminated intravascular coagulation. N. Engl. J. Med. 341, 586–592
32 Klein, N.J. et al. (1992) Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J. Cell Sci. 102, 821–832
33 Klein, N.J. et al. (1996) The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis. J. Infect. Dis. 173, 172–179
34 Conway, E.M. and Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell. Biol. 8, 5588–5592
35 Fukudome, K. and Esmon, C.T. (1994) Identification, cloning and regulation of a novel endothelial cell protein C receptor. J. Biol. Chem. 269, 26486–26491
36 Takano, S. et al. (1990) Plasma thrombomodulin in health and disease. Blood 76, 2024–2029
37 Faust, S.N. et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 345, 408–416
38 Liaw, P.C.Y. et al. (2001) Carboxypeptidase R is an inactivator of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799–1805
39 Fisher, C.J. and Yan, S.B. (2000) Protein C levels as a prognostic et al
40 Souter, P.J. et al
41 Altieri, D.C. et al
42 Altieri, D.C.
43 Ye, J.
44 Kaneider, N.C. et al. (1992) The fifth and sixth growth factor-like domains of thrombomodulin required for efficient thrombin-activable fibrinolysis receptor. J. Biol. Chem. 267, 11023–11028
45 Ostrovsky, L. et al. (1997) Crystal structures of native and thrombin-activated protein C receptor and a bound phospholipid. J. Biol. Chem. 272, 24951–24954
46 Liu, L-W. et al. (2000) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96, 2302–2310
47 Liu, L-W. et al. (2001) Syndecan-4 as antithrombin receptor of human neutrophils. Biochem. Biophys. Res. Commun. 287, 42–46
48 Riewald, M. et al. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882
49 Shibata, M. et al. (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of stroke. Circulation 103, 1799–1805
50 Oganessian, V. et al. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. J. Biol. Chem. 277, 25421–25434
51 Esmon, C.T. (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. 264, 4743–4746
52 Conway, E.M. et al. (2002) The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor-κB and mitogen-activated protein kinase pathways. J. Exp. Med. 196, 565–577
53 Hancock, W.W. et al. (1995) Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60, 1525–1532
54 White, B. et al. (2000) Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor-κB (NF-κB) and tumour necrosis factor-α (TNF-α) production in the THP-1 monocytic cell line. Br. J. Haematol. 110, 130–134
55 Yakes, M. et al. (2002) Activated protein C inhibits lipopolysaccharide-induced tumour necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb. Haemost. 88, 267–273
56 Murphy, C. et al. (2001) Activated protein C inhibits upregulation of both tissue factor and TFPI in endotoxin stimulated monocytes. Thromb. Haemost. Suppl. P509 (Abstr.)
57 Shu, F. et al. (2000) Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor dependent manner. FEBS Lett. 477, 208–212
58 Riewald, M. et al. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882
59 Shibata, M. et al. (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799–1805
60 Oganessian, V. et al. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. J. Biol. Chem. 277, 24951–24954
61 Moody, D.B. et al. (2000) CD14-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404, 884–888
62 Hong, S. et al. (1999) Lipid antigen presentation in the immune system learned from CD1d knockout mice. ImmunoL Rev. 169, 31–44
63 Hurtado, V. et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for foetal death. Blood (in press)
64 Burstein, S.A. (1997) Cytokines, platelet production and hemostasis. Platelets 8, 93–104
65 Pendurthi, U.R. et al. (1997) Binding of factor VIIα to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase. Proc. Natl. Acad. Sci. U. S. A. 94, 12598–12603
66 Miller, D.L. et al. (1998) CD40L–CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol. 63, 373–379
67 Andre, P. et al. (2002) CD40L stabilizes arterial thrombosis by a β3 integrin-dependent mechanism. Nat. Med. 8, 247–252
68 Henn, V. et al. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591–594
69 Bernard, G.R. et al. (2000) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709
70 Warren, B.L. et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J. Am. Med. Assoc. 286, 1859–1867
71 Abraham, E. et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J. Am. Med. Assoc. 290, 238–247
72 Minnema, M.C. et al. (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95, 1117–1123
73 Creasey, A.A. et al. (1993) Tissue factor pathway inhibitor (TFPI) reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91, 2850–2860
74 Esmon, C.T. (2000) Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 95, 1113–1116
75 Esmon, C.T. (2004) Why do animal models (sometimes) fail to mimic human sepsis? Crit. Care Med. 32(Suppl), S219–S222
76 Oliver, J.A. et al. (2002) Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 100, 539–546
77 Esmon, C.T. et al. (1993) Cell mediated events that control blood coagulation and vascular injury. Annu. Rev. Cell Biol. 9, 1–26
78 Baglin, T.P. et al. (2002) Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. U. S. A. 99, 11079–11084